Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

NCT01876953 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Due to the budget issues, the study discontinued at Phase II.

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: cytarabine
DRUG: idarubicin
DRUG: dasatinib
OTHER: laboratory biomarker analysis

Sponsor

City of Hope Medical Center

Collaborators

[object Object]